Global E Online Ltd vs Zimmer Biomet Holdings Inc — how do they compare? Global E Online Ltd trades at $46.61 (market cap $6.87B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.7× Global E Online Ltd's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| GLBE | ZBH | |
|---|---|---|
Market Cap | $6.87B | $18.55B |
Sector | Technology | Health |
52-Week High | $42.32 | $107.71 |
52-Week Low | $27.54 | $79.58 |
Enterprise Value | $6.34B | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $42.32, up 3.17% in the past 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings have been mixed, with a beat in Q4 2025 but a miss in Q1 2026. The company reported 2025 revenue of $962.20 million and net income of $68.27 million, with profitability improving into 2026. Key developments include the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorized by the board.
GLBE presents a growth opportunity with robust analyst support—100% buy ratings and a consensus price target of $44.75, suggesting upside potential. However, risks include high valuation multiples like a P/E of 61.33, competitive pressures in e-commerce enablement, and insider selling by the CEO. Investors should weigh the strong growth trajectory against premium valuation and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →